Literature DB >> 11397843

The relationship between steroidogenic factor 1 and DAX-1 expression and in vitro gonadotropin secretion in human pituitary adenomas.

S J Aylwin1, J P Welch, C L Davey, J F Geddes, D F Wood, G M Besser, A B Grossman, J P Monson, J M Burrin.   

Abstract

The orphan nuclear receptors, steroidogenic factor 1 (SF-1) and DAX-1, are involved in gonadotroph differentiation, and SF-1 has been shown to activate the LH-beta and glycoprotein hormone alpha-subunit (alpha GSU) gene promoters. Pituitary adenomas from 34 patients [13 somatotroph tumors, 4 prolactinomas, and 17 clinically nonfunctioning pituitary adenomas (NFPAs)] were enzymatically dispersed and cultured in vitro for 48 h. Tissue culture medium was collected and assayed for LH, FSH, and alpha GSU; messenger RNA was extracted from adherent cells, and expression of SF-1 and DAX-1 messenger RNA was determined by RT-PCR and verified by direct DNA sequencing. The presence of DAX-1 protein in tumor tissue was confirmed by immunocytochemistry. DAX-1 was demonstrated in all NFPAs, 7 of 13 somatotroph tumors and 0 of 4 prolactinomas. SF-1 expression occurred in 8 of 16 NFPAs, 4 of 12 somatotroph tumors, and 1 of 4 prolactinomas. LH secretion in vitro was greater in NFPAs that were SF-1 positive (P < 0.05). Neither FSH secretion nor alpha GSU secretion in vitro were significantly related to the expression of SF-1 or DAX-1. SF-1-positive somatotroph tumors immunostained positively for LH-beta and/or FSH-beta and secreted gonadotropins in vitro. SF-1 expression is associated with the in vitro secretion of LH by NFPAs. A proportion of somatotroph tumors also express SF-1 and DAX-1 and secrete gonadotropin hormones in vitro.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11397843     DOI: 10.1210/jcem.86.6.7531

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  6 in total

1.  Immunonegative "null cell" adenomas and gonadotropin (Gn) subunit (SUs) immunopositive adenomas share frequent expression of multiple transcription factors.

Authors:  Yudo Ishii; Masanori Suzuki; Susumu Takekoshi; Noboru Egashira; Michio Yamazaki; Shunsuke Miyai; Naoko Sanno; Akira Teramoto; Robert Yoshiyuki Osamura
Journal:  Endocr Pathol       Date:  2006       Impact factor: 3.943

2.  Silent corticogonadotroph adenomas: clinical and cellular characteristics and long-term outcomes.

Authors:  Odelia Cooper; Anat Ben-Shlomo; Vivien Bonert; Serguei Bannykh; James Mirocha; Shlomo Melmed
Journal:  Horm Cancer       Date:  2010-04       Impact factor: 3.869

3.  ACTH and alpha-subunit are co-expressed in rare human pituitary corticotroph cell adenomas proposed to originate from ACTH-committed early pituitary progenitor cells.

Authors:  Masanori Suzuki; Noboru Egashira; Hanako Kajiya; Takeo Minematsu; Susumu Takekoshi; Shigeyuki Tahara; Naoko Sanno; Akira Teramoto; Robert Yoshiyuki Osamura
Journal:  Endocr Pathol       Date:  2008       Impact factor: 3.943

Review 4.  Clinical and Pathological Aspects of Silent Pituitary Adenomas.

Authors:  Juliana Drummond; Federico Roncaroli; Ashley B Grossman; Márta Korbonits
Journal:  J Clin Endocrinol Metab       Date:  2019-07-01       Impact factor: 5.958

5.  Gonadotroph tumours with a low SF-1 labelling index are more likely to recur and are associated with enrichment of the PI3K-AKT pathway.

Authors:  Richard A Hickman; Jeffrey N Bruce; Marc Otten; Alexander G Khandji; Xena E Flowers; Markus Siegelin; Beatriz Lopes; Phyllis L Faust; Pamela U Freda
Journal:  Neuropathol Appl Neurobiol       Date:  2020-12-20       Impact factor: 8.090

6.  Identification of two novel CT antigens and their capacity to elicit antibody response in hepatocellular carcinoma patients.

Authors:  X-Y Dong; Y-R Su; X-P Qian; X-A Yang; X-W Pang; H-Y Wu; W-F Chen
Journal:  Br J Cancer       Date:  2003-07-21       Impact factor: 7.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.